Lycia Lands a $317M IPO for Inflammation Drugs Based on Nobel Prize-Winning Science

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 25 Oct, 16:13 UTC

Lycia Therapeutics’ protein-degrading drugs are based on the research of Carolyn Bertozzi, a Stanford chemistry professor and Nobel laureate. Lycia’s lead drug candidate is in development for food allergy, where it could compete against the blockbuster Roche drug Xolair. The post Lycia Lands a…